HOME >> MEDICINE >> NEWS
Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years

THOUSAND OAKS, Calif., November 13, 2006 -- Amgen (NASDAQ: AMGN), today announced that data from an ongoing open-label, multinational, phase 4 extension study showed that patients with ankylosing spondylitis (AS) who received treatment with Enbrel? (etanercept) experienced sustained improvement in signs and symptoms, spinal mobility and physical function over 148 to 160 weeks of therapy. These results are consistent with an ENBREL phase 3 clinical trial at 24 weeks. The 160-week results will be presented at the American College of Rheumatology (ACR) Scientific Meeting in Washington, D.C.

"These data demonstrate that ENBREL can provide substantial long-term improvement in AS symptoms such as total back pain and spinal mobility," said Joachim Sieper, M.D., professor of rheumatology, Charite University in Berlin, Germany. "Because AS is a chronic inflammatory disease that requires ongoing management, it is important to offer patients a treatment option that is effective, has an established safety profile, and can be used over the long-term."

Data presented at ACR showed that 59 patients who received open-label ENBREL treatment for up to 160 weeks experienced sustained clinical improvements. Overall, 78 percent of patients (n=46) continuing treatment with ENBREL achieved a 20 percent improvement in the Assessment on Ankylosing Spondylitis Response Criteria (ASAS 20) after 160 weeks of treatment. ASAS is a composite measure of improvement in AS symptoms that include total back pain, patient assessment of disease activity, inflammation and physical function. Thirty-one percent of patients (n= 18) achieved partial remission at week 160. Partial remission, as defined by ASAS, is a low disease activity level (score < 20 units out of 100 in each of the four ASAS criteria).

Additional ENBREL data presented at ACR from this phase 4 extension study show that improvement in spinal mobility was also sustained through 148 to 160 weeks of
'"/>

Contact: Sonia Fiorenza
805-447-1604
Porter Novelli
13-Nov-2006


Page: 1 2 3

Related medicine news :

1. Rheumatoid arthritis patients can benefit from Enbrel in combination with methotrexate
2. Sports concussion research using fMRI provides insight for safe return-to-play decisions
3. Fluorescence diffuse optical tomography provides high contrast, 3-D look at breast cancer
4. Daytrana provides significant effectiveness in both boys and girls with ADHD
5. New book provides unprecedented look at role of religion over a lifetime
6. New edition of medical reference book provides the latest in hematology
7. Lung cancer screening regimen provides opportunity for cure
8. MERLIN TIMI-36 study provides new safety and efficacy data for unique anti-anginal therapy
9. IceSAR campaign provides glimpse of future Sentinel-1 images over ice
10. Darunavir with FUZEON provides HIV patients a better chance to reach undetectable viral load
11. Optical technique provides improved virtual biopsies of internal surfaces

Post Your Comments:
(Date:7/29/2015)... ... July 29, 2015 , ... Avatar Solutions has received official ... for PQRS Survey. , The CAHPS for PQRS Survey collects information about ... or more eligible providers must participate or they will receive a 2% penalty in ...
(Date:7/29/2015)... NY (PRWEB) , ... July 29, 2015 , ... This ... on a positive surrogacy journey from a treasured member of the CARE extended family. ... Puerto Vallarta hopes to help intended parents across the globe gain a newfound perspective ...
(Date:7/29/2015)... , ... July 29, 2015 , ... Andrzej Klos, M.D., ... Klos, a board-certified pediatrician for nearly 38 years, is motivated each and every day ... commitment to his profession shine alongside his many awards and accolades, which include multiple ...
(Date:7/29/2015)... ... , ... Potomac Pilates, an elite Washington, D.C. metro area-based Pilates studio, is ... by Potomac Pilates. On Thursday, July 30, Potomac Pilates will unveil its new ... Pilates will continue to offer the same classes and personal experiences their clients know ...
(Date:7/29/2015)... ... July 29, 2015 , ... Ticket Down is a ... Brazil vs. USA . , The international soccer schedule of matches ... exponentially and now on September 8th, one of the world’s greatest teams, Brazil, will ...
Breaking Medicine News(10 mins):Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 2Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 3Health News:Heartfelt Interview Shows Extraordinary Impact of CARE Surrogacy Center Mexico 2Health News:Heartfelt Interview Shows Extraordinary Impact of CARE Surrogacy Center Mexico 3Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 3Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 3
(Date:7/29/2015)... N.J. and BERKELEY, Calif. ... and Plexxikon Inc., a member of the Daiichi Sankyo ... of Medicine (NEJM) published clinical trial results demonstrating ... inhibitor, induced prolonged tumor regressions in most patients with ... neoplasm of the joint or tendon sheath. ...
(Date:7/29/2015)... 2015  Hologic, Inc. (NASDAQ: HOLX ) announced ... quarter ended June 27, 2015.  Quarterly revenues of $693.9 ... on a constant currency basis.  GAAP earnings per share ... $0.43 increased 16.2%. "Our third quarter financial ... building a company that can grow sustainably on both ...
(Date:7/29/2015)... , July 29, 2015 Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... on Monday, August 10, 2015 after the close of ... conference call and webcast on Monday, August 10, 2015 ... discuss the results and corporate developments. For ...
Breaking Medicine Technology:Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5Hologic Announces Financial Results for Third Quarter of Fiscal 2015 2Hologic Announces Financial Results for Third Quarter of Fiscal 2015 3Hologic Announces Financial Results for Third Quarter of Fiscal 2015 4Hologic Announces Financial Results for Third Quarter of Fiscal 2015 5Hologic Announces Financial Results for Third Quarter of Fiscal 2015 6Hologic Announces Financial Results for Third Quarter of Fiscal 2015 7Hologic Announces Financial Results for Third Quarter of Fiscal 2015 8Hologic Announces Financial Results for Third Quarter of Fiscal 2015 9Hologic Announces Financial Results for Third Quarter of Fiscal 2015 10Hologic Announces Financial Results for Third Quarter of Fiscal 2015 11Hologic Announces Financial Results for Third Quarter of Fiscal 2015 12Hologic Announces Financial Results for Third Quarter of Fiscal 2015 13Hologic Announces Financial Results for Third Quarter of Fiscal 2015 14Hologic Announces Financial Results for Third Quarter of Fiscal 2015 15Hologic Announces Financial Results for Third Quarter of Fiscal 2015 16Hologic Announces Financial Results for Third Quarter of Fiscal 2015 17Hologic Announces Financial Results for Third Quarter of Fiscal 2015 18Hologic Announces Financial Results for Third Quarter of Fiscal 2015 19Hologic Announces Financial Results for Third Quarter of Fiscal 2015 20Hologic Announces Financial Results for Third Quarter of Fiscal 2015 21Hologic Announces Financial Results for Third Quarter of Fiscal 2015 22Hologic Announces Financial Results for Third Quarter of Fiscal 2015 23Hologic Announces Financial Results for Third Quarter of Fiscal 2015 24Hologic Announces Financial Results for Third Quarter of Fiscal 2015 25Asterias Biotherapeutics to Report Second Quarter Results on August 10, 2015 2
Cached News: